Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG106 in advanced solid tumors and Non-Hodgkin Lymphoma
NCT03707093Phase 1Completed
- Sponsor
- Adagene
- Start
- Sep 2018
- Primary completion
- Jan 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADG106 in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Adagene. Primary endpoints: Dose-limiting toxicities at 42 days and Adverse Events. Started Sep 2018; status: completed.
02
Drugs
ADG106
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03707093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707093.